Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a
PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients
with advanced, non-small cell lung cancer.